STOCK MARKET BSE NSE

‘Form Ethics Panel for clinical trials’

JIPMER Director Dr T S Ravikumar emphasised that the recent guidelines for registration of ethics committee in clinical trials of drugs be followed in order to protect the safety and welfare of the research participants.

Published: 04th April 2013 11:19 AM  |   Last Updated: 04th April 2013 11:19 AM   |  A+A-

JIPMER Director Dr T S Ravikumar emphasised that the recent guidelines for registration of ethics committee in clinical trials of drugs be followed in order to protect the safety and welfare of the research participants.

Speaking at a one day workshop on Bioethics , organised by the Division of Research, JIPMER, he expressed the  need for comparative effectiveness research.

Dr C Adithan Senior Professor, Pharmacology, and organising secretary, said that as per notification on registration of ethics committee,  all ethics committees have to be registered for examining and approving clinical trial protocol. He also explained about the composition of ethics committee, forum for ethics committee and compensation clause for such committees that are mentioned in government notification.

Dr Nandini K Kumar who  was closely involved in the finalisation of ICMR’s Ethical Guidelines of 2000 and 2006, spoke about the past unethical practices done in clinical trials that necessitated the framing of guidelines and rules for safeguarding the interest of clinical trial participants. This was followed by a talk by Dr Ramakrishnan, Scientist ‘F’ & Division Head, Health Systems Research and Bio-Ethics, National Institute of Epidemiology, ICMR, who explained the Indian guidelines on good clinical practice.

Dr Sridhar, member of JIPMER Ethics Committee and Professor of Biochemistry, highlighted the components of informed consent form and the problems in obtaining informed consent in vulnerable population.

The workshop was organised in the backdrop of recent  concerns regarding clinical trial-related Serious Adverse Events (SAEs) and compensation provided to the research participants in case of clinical trial-related injuries or death. In view of this, Government of India had taken several steps to strengthen the regulatory mechanisms for the conduct of clinical trials in India. 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp